The global stem cell therapy market is projected to reach USD 31.41 billion by 2030, growing at a CAGR of 13.73% during the forecast period from 2023 to 2030. The market size was estimated at USD 11.22 billion in 2022 and is expected to expand to USD 24.29 billion by 2028. Factors driving the growth of the market include accelerated funding for stem cell therapies, rising interest in stem cell-b..
The Biden administration has implemented inflation penalties on 43 Medicare Part B drugs to reduce costs for older Americans, following the imposition of fines on 27 drugs in March. The Inflation Reduction Act (IRA) requires pharmaceutical manufacturers to justify price increases exceeding the inflation rate, with financial penalties imposed if justifications are found insufficient. Under the IR..
AstraZeneca and Sanofi have received unanimous backing from the FDA’s Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, for use in the pediatric setting. Nirsevimab is an investigational long-acting antibody that targets and binds to the part of the RSV virus that attaches to the host’s cells. If approved, nirsevimab would become the first i..
The gene editing race between Editas Medicine and Vertex Pharmaceuticals with CRISPR Therapeutics has heated up as both companies released positive data for their sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) hopeful treatments. Editas Medicine unveiled early data from the RUBY and EdiTHAL trials on Friday, demonstrating the potential of its gene editor EDIT-301 in t..
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee has unanimously supported Eisai and Biogen's Leqembi (lecanemab) for the treatment of Alzheimer's disease. This indicates that the FDA is likely to grant full approval before July 6th, as it usually follows its advisory committee's recommendations. The FDA released briefing documents on Wednesday that showed agency staff be..
AstraZeneca has announced a partnership with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder. The collaboration involves the use of Quell's T-regulatory (Treg) cell engineering toolbox to develop autologous multi-modular Treg cell therapies, which will be manufactured through to the end of the first-in-human clinical study. AstraZeneca has initial..
Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, has received FDA approval for its generic version of Dexmedetomidine Hydrochloride Injection, which is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. The drug will be available in 50mL and 100mL and will help reduce recent supply issues experience..
Medical technology company Inspire Medical Systems has received approval from the US Food and Drug Administration (FDA) for an expanded indication. The decision means that the upper limit of the Apnea Hypopnea Index (AHI) has been raised to 100 events per hour from 65, while the Body Mass Index (BMI) warning in labeling has been increased to 40 from 32. This approval allows Inspire's proprietary..
ACROBioSystems' Aneuro brand has partnered with Diagnostic Biochips to launch in vivo electrophysiology solutions for neuroscience research. The collaboration aims to accelerate neurological drug discovery and commercialization. Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain's field potential and ele..
